Abbott Laboratories $ABT Shares Acquired by IFM Investors Pty Ltd

IFM Investors Pty Ltd increased its stake in shares of Abbott Laboratories (NYSE:ABT) by 4.3% in the 1st quarter, HoldingsChannel reports. The firm owned 379,101 shares of the healthcare product maker’s stock after purchasing an additional 15,721 shares during the period. IFM Investors Pty Ltd’s holdings in Abbott Laboratories were worth $38,922,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of ABT. Vanguard Group Inc. grew its position in shares of Abbott Laboratories by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock worth $21,995,501,000 after buying an additional 2,402,408 shares in the last quarter. State Street Corp raised its holdings in Abbott Laboratories by 2.1% in the fourth quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock valued at $10,004,880,000 after acquiring an additional 1,627,791 shares in the last quarter. Capital International Investors raised its holdings in Abbott Laboratories by 2.6% in the fourth quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock valued at $7,922,519,000 after acquiring an additional 1,614,706 shares in the last quarter. J. Stern & Co. LLP lifted its stake in Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after acquiring an additional 39,005,451 shares during the last quarter. Finally, Capital Research Global Investors grew its holdings in Abbott Laboratories by 1.0% during the 4th quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock worth $4,907,523,000 after acquiring an additional 400,400 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau bought 2,200 shares of the firm’s stock in a transaction dated Thursday, April 23rd. The stock was acquired at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the purchase, the chief financial officer owned 2,200 shares of the company’s stock, valued at approximately $201,300. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Daniel J. Starks purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The stock was bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the transaction, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Trading Down 2.2%

ABT opened at $90.68 on Wednesday. The firm has a market cap of $157.95 billion, a price-to-earnings ratio of 25.40, a price-to-earnings-growth ratio of 1.60 and a beta of 0.63. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The business’s 50 day moving average is $88.91 and its two-hundred day moving average is $104.84. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. The business had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company’s revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, research analysts predict that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.8%. Abbott Laboratories’s dividend payout ratio is currently 70.59%.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Wall Street continues to view Abbott as a strong income name, with a TipRanks roundup highlighting ABT as one of three dividend aristocrats currently rated a Strong Buy by analysts. 3 Dividend Aristocrat Stocks Wall Street Loves Right Now — June 30, 2026
• Positive Sentiment: Wells Fargo reiterated its Buy rating on Abbott, reinforcing the view that the stock still has analyst support despite recent volatility. Wells Fargo Remains a Buy on Abbott Laboratories (ABT)
• Positive Sentiment: Abbott’s largest Medical Devices segment is being positioned for a new growth phase, helped by diabetes, heart rhythm, and electrophysiology product momentum. How Abbott’s Largest Segment Is Preparing for the Next Growth Phase
• Neutral Sentiment: News that the U.S. DOJ closed its criminal probe into Abbott’s infant formula plant removes a major legal uncertainty, but reports also say the company is still facing a proposed civil settlement and penalties under the False Claims Act, so the issue is not fully resolved. US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports
• Negative Sentiment: Recent market coverage says ABT underperformed in Monday’s session and settled lower, indicating investors were already cautious before the latest news flow. Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on ABT shares. Daiwa Securities Group lowered shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective on the stock. in a report on Wednesday, April 22nd. Benchmark lowered their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Oppenheimer cut their price target on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Wells Fargo & Company decreased their price target on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Finally, Evercore lowered their price objective on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $118.30.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.